NovoCure Limited
NVCR
$17.96
$0.070.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.82% | 18.55% | 24.07% | 3.25% | -36.75% |
| Total Depreciation and Amortization | 6.01% | 1.76% | -3.13% | 1.84% | 1.13% |
| Total Amortization of Deferred Charges | 12.06% | 12.06% | 5.47% | 5.47% | 5.47% |
| Total Other Non-Cash Items | 40.94% | 45.82% | -18.51% | -23.80% | -17.64% |
| Change in Net Operating Assets | -237.91% | -112.30% | -19.01% | -85.61% | -91.83% |
| Cash from Operations | 65.46% | 64.04% | 40.02% | -223.68% | -596.86% |
| Capital Expenditure | -27.12% | -58.18% | -52.54% | -48.31% | -46.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -192.22% | -146.10% | 234.97% | 113.44% | 2,226.91% |
| Cash from Investing | -212.89% | -176.16% | 53.95% | 94.06% | 964.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -430,333.33% | -129,030.00% | -75,858.82% | -53,704.17% | 89.29% |
| Issuance of Common Stock | 5.01% | -60.08% | -68.04% | -67.55% | -38.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 783.19% | 472.08% | 417.96% | 345.92% | -38.50% |
| Foreign Exchange rate Adjustments | 220.59% | -232.82% | 79.07% | -139.47% | 209.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -221.13% | -160.34% | 137.35% | 105.21% | 5,526.42% |